Evotec stock falls after a 2026 guidance cut
Published on 08/14/2026 at 14:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock is under pressure after the company cut its 2026 outlook on August 13, 2026, following second-quarter revenue of €143.5 million and adjusted group EBITDA of -€20.8 million. The latest numbers also showed first-half 2026 revenue of €300.1 million and adjusted EBITDA of -€42.7 million, a reminder that profitability remains the main issue for investors.
Guidance reset
The company now expects 2026 revenue of €570 million to €610 million, down from an earlier range of €700 million to €780 million, while adjusted EBITDA is projected at a loss of €70 million to €105 million. That is a clear comparison: the top end of revenue guidance was reduced by €170 million, and the EBITDA outlook moved from a possible profit of up to €40 million to a loss range.
For investors, the key question is whether the lower guidance mainly reflects timing or a more durable setback in commercial conversion. The company said delayed milestone payments and slower revenue recognition weighed on the quarter, which helps explain why the first half still left adjusted EBITDA deep in negative territory.
Market reaction
On August 14, 2026, the shares traded at €3.54 in Xetra morning trading, after starting the session at €3.56 and touching €3.53. The stock was down 0.2 percent at the time of the update, and the day did little to offset a year-to-date decline of 30.97 percent shown by the market overview.
That gap between the 2026 guidance reset and the share price matters. With revenue now guided to €570 million to €610 million and adjusted EBITDA at -€70 million to -€105 million, the market is still pricing in a difficult second half.
What Evotec sells
Evotec's core business is drug discovery and development partnerships, where milestone payments and project progress drive revenue recognition. That model makes the pace of commercial conversion especially important when milestone timing shifts into later periods.
Price and setup
As of August 14, 2026, Evotec shares traded at €3.54 on Xetra. The stock remained far below the €6.03 analyst price target consensus reported in market coverage, leaving valuation tied closely to execution rather than near-term momentum.
More on Evotec stock
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: Xetra
Sector / Industry: Health Care / Biotechnology
Index membership: MDAX
